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original work is propObjective: Development of immunogens that elicit an anti-HIV-1 broadly neutralizing
antibody (bnAb) response will be a key step in the development of an effective HIV-1
vaccine. Although HIV-1 bnAb epitopes have been identified and mechanisms of action
studied, current HIV-1 envelope-based immunogens do not elicit HIV-1 bnAbs in
humans or animal models. A better understanding of how HIV-1 bnAbs arise during
infection and the clinical factors associated with bnAb development may be critical for
HIV-1 immunogen design efforts.
Design and methods: Longitudinal plasma samples from the treatment-naive control
arm of the ShortPulse Anti-Retroviral Therapy at Seroconversion (SPARTAC) primary HIV-
1 infection cohort were used in an HIV-1 pseudotype neutralization assay to measure the
neutralization breadth, potency and specificity of bnAb responses over time.
Results: In the SPARTAC cohort, development of plasma neutralization breadth and
potency correlates with duration of HIV infection and high viral loads, and typically
takes 3–4 years to arise. bnAb activity was mostly directed to one or two bnAb epitopes
per donor and more than 60% of donors with the highest plasma neutralization having
bnAbs targeted towards glycan-dependent epitopes.
Conclusion: This study highlights the SPARTAC cohort as an important resource for
more in-depth analysis of bnAb developmental pathways.
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2074 AIDS 2021, Vol 35 No 13IntroductionA key goal in HIV-1 vaccine development is the
elicitation of antibodies that potently neutralize a broad
range of HIV-1 strains [1]. Such antibodies, termed
broadly neutralizing antibodies (bnAbs), typically develop
2–3 years after infection in 10–30% of HIV-infected
individuals [2–6], although in rare occasions can be
detected within the first year of infection [7]. Although
bnAbs are unable to control disease, when passively
transferred to macaques, they can prevent infection in
chimeric simian-HIV (SHIV) challenge models [8,9],
highlighting the importance of eliciting a robust bnAb
response in vaccine development. The virally encoded
HIV-1 surface glycoprotein Env is the sole target for
bnAbs and consists of a trimer of gp120-gp41 hetero-
dimers. Several Env epitopes have been identified that are
targeted by bnAbs isolated from chronically infected
individuals. These include the CD4-binding site [10,11]
(e.g. VRC01, N6), the membrane proximal external
region (MPER) [12,13] (e.g. 4E10, 10E8), the fusion
peptide [14,15] (e.g. ACS202, VRC34.01), and glycan-
dependant epitopes centred around the N332-V3-region
[16–18] (e.g. PGT121, PGT128, PCDN38A), the
N160/V2-apex [16,19,20] (e.g. PG9, PGT145,
CAP256-VRC26) and N-glycans at the gp120-gp41
interface [21,22] (e.g. PGT151, 35O22). HIV-1 bnAbs
have unusual characteristics including high levels of
somatic hypermutation, long CDRH3 regions, insertions
and deletions and framework mutations [23]. bnAbs are
thought to arise following multiple rounds of viral escape
and antibody somatic hypermutation where the immune
response is progressively targeted towards the most
conserved regions of HIV-1 Env [24,25]. However,
immunization with soluble recombinant state-of-the-art
Env trimers has so far not generated antibodies capable of
neutralizing a broad range of HIV-1 isolates [26–28].
Therefore, understanding how bnAbs arise during natural
infection, and the clinical and virological correlates
relating to their elicitation, may be critical for the
development of immunogens capable of eliciting
protective bnAbs through vaccination.
As clinical guidelines have moved towards early
antiretroviral therapy (ART) following diagnosis
[29,30], there is great value in historic longitudinal
clinical cohorts for studying bnAb development. There-
fore, we set out to phenotype bnAb development in
individuals diagnosed with primary HIV-1 infection and
randomized to the control arm of the Short Pulse Anti-
Retroviral Therapy at Seroconversion (SPARTAC) trial
[31]. The SPARTAC trial was initiated in 2003 to
determine whether short-term ART during primary
HIV-1 infection (either 12 or 48 weeks) could lengthen
the time before long-term ARTwas required. Individuals
were recruited to the trial within 6 months of HIV-1
infection. Within this trial, one-third of 376 study
participants were randomly allocated to no immediateART, which reflected standard clinical practice at the
time. Longitudinal plasma and peripheral blood mono-
nuclear cells (PBMCs) were collected sequentially until
CD4 levels declined to 350 cells/ml and ART was
initiated, or conclusion of the trial (which ever came
first). Participants were recruited in the UK, Ireland,
South Africa, Uganda, Italy, Spain, Brazil and Australia,
and therefore included multiple HIV-1 clades. Using
clinical samples from participants enrolled into the control
arm, we set out to: identify donors that developed bnAbs,
identify clinical factors that associate with bnAb
induction, study kinetics of bnAb development and
study specificity of bnAb responses.
Plasma taken either just prior to initiation of ARTor just
prior to termination of the trial from 8 of 50 donors (16%)
in the control arm were found to neutralize at least five
viruses from a cross-clade 6-virus indicator panel [4].
Development of neutralization breadth and potency was
shown to strongly correlate with higher viral loads and
longer infection times. In the donors with highest breadth
and potency, heterologous neutralization appeared
between 50 and 108 weeks post infection and neutraliza-
tion breadth typically took 132–204 weeks to develop
and arose in a stepwise manner. BnAb activity was mostly
directed to one or two epitopes per donor with more than
60% of donors with neutralization scores more than 0.9
having bnAbs targeted towards glycan-dependent epi-
topes. This study highlights the SPARTAC cohort as an
important resource for more in-depth analysis of bnAb
developmental pathways that can inform HIV-1 immu-
nogen design strategies.Methods
Cohort design and ethics
The design of the SPARTAC trial is reported elsewhere
[31]. SPARTAC was an international randomized control
trial of early ART, comparing 12 or 48 weeks of ART
followed by treatment interruption with no immediate
treatment. Three hundred and sixty-six adults within an
estimated 6 months from seroconversion were recruited.
All participants gave written informed consent. Ethical
approval for collection of these samples was originally
approved by: Medicines and Healthcare products
Regulatory Agency (UK), Ministry of Health (Brazil),
Irish Medicines Board (Ireland), Medicines Control
Council (South Africa) and The Uganda National
Council for Science and Technology [31].
Reagents
The following reagents were obtained through the NIH
AIDS Reagent Program: HIV-1 RSC3 (Cat#12042) and
HIV-1 RSC3 D371I/P363N (Cat#12362) recombinant
proteins from Drs Yang, Kwong, Nabel [32,33], and
HIV-1 Consensus B MPER Peptide (Cat#11938).
Neutralizing antibodies in SPARTAC cohort Granger et al. 2075Env-pseudovirus production and neutralization
assays
HIV-1 pseudovirus was generated in HEK-293T cells as
described [6,34]. HEK-293T cells were transfected with
plasmids expressing the HIV-1 virus backbone PSG-
3DEnv and full-length Env at a ratio of 2 : 1 using
polyethylenimine (PEI) (1 mg/ml; 1 : 3 PEI/total DNA;
Polysciences, Warrington, Pennsylvania, USA). Virus
supernatants were harvested after 72 h.
Plasma neutralizing activity was assessed using TZM-bl
target cells (expressing CD4, CXCR4 and CCR5
receptors) as described previously [6,34]. TZM-bl cells
were seeded 24 h in advance in a 96-well plate
(10 000 cells/well). Heat inactivated plasma (56 oC, 1 h)
was serially diluted and preincubated with virus for 1 h
before addition to the cells. Luminescence was quantified
after 72 h via lysis and addition of Bright-Glo luciferase
substrate (Promega, Madison, Wisconsin, USA). ID50 was
determined using nonlinear regression (GraphPad Prism).
Calculation of neutralization score
The cross-clade indicator panel included JR-CSF (clade B),
94UG103 (clade A), 92RW020 (clade A), IAVI C22 (clade
C), 92TH021 (clade CRF01_AE) and 92BR020 (clade B)
[4]. VSV-G was used as a control for nonspecific
neutralization. Neutralization breadth and potency of
individual plasma samples were determined by a neutraliza-
tion score defined as the weighted average of log-
transformed ID50 values across the cross-clade virus panel:
[score ¼ average (log3 (dilution/100)þ 1)] as previously
described [24]. All titres below the limit of detection (1 : 50)
were assigned a value of 33 for purposes of calculating a
neutralization score. Log-transformed values with 0.0
represent a sample with undetectable neutralization.
Serum mapping by neutralization
N-glycan sites were removed through an Asn to Ala or Asn
to Lys mutation in the consensus sequence (NXT/S) as
previously reported [35]. Variant viruses were selected
based on plasma neutralization activity and included; JR-
CSF (N332A, N160K, N611AþN637A), IAVI C22
(N160K, N332A, E647A), 92TH021 (N334A), 94UG103
(N160K, N332A), 92RW020 (N160K, N332A,
N611AþN637A), 92BR020 (N160K, N332A).
Membrane proximal external region peptide and
RSC3 competition neutralization assay
Patient plasma was preincubated with either MPER
peptide (50 mg/ml) or RSC3 glycoprotein (25 mg/ml) for
1 h before addition of HIV-1 pseudovirus. The plasma/
MPER or plasma/RSC3 pseudovirus mixture was
incubated for a further 1 h before addition of TZM-bl
cells. Neutralization was determined as described above.
RSC3 ELISA
Wells were coated with 50 ng of RSC3 or RSC3 mutant
(RSC3D371I/P363N) [32,33] overnight (4 8C). Plateswere washed five times with PBS-containing 0.05%
Tween20 (PBS-T) and blocked with blocking buffer (5%
nonfat milk in PBS-T) for 1 h (RT). Serial diluted plasma
(starting at 1 : 50) was incubated for 2 h (RT). Plates were
washed five times with PBS-T. Secondary Ab (goat-
antihuman F(ab’)2-AP, (Invitrogen, Paisley, UK, Cat#
31312, 1 : 1000) was added for 1 h and plates washed. p-
Nitrophenyl phosphate substrate (Sigma-Aldrich, Gil-
lingham, Dorset, UK) was added and optical denisty
measured at 405 nm.
Statistics
Statistical analyses were performed using GraphPad Prism
8; GraphPad Software, San Diego, California, USA).
Differences between groups were analysed with the
Mann–Whitney U test or ANOVA. Spearman’s rank
correlation was used to examine the associations between
the nonparametric factors studied. Principle component
analysis was performed using R, R studio and the package
FactoMineR. Univariate and multivariate linear regres-
sion analyses were performed using GraphPad Prism and
R. For multivariate analysis, neutralization score was used
as dependent factor and weeks post recruitment, start
time of ARTand logarithmic viral load at recruitment and
neutralization score were used as potential predictors. The
two parameters with the highest P value (start time of
ART and logarithmic viral load at recruitment) were
further eliminated and tested in multivariate analysis using
neutralization score as dependent factor. P values less than
0.05 were considered significant.Results
Broadly neutralizing antibody responses in the
participants randomized to the Short Pulse Anti-
Retroviral Therapy at Seroconversion cohort
control arm
Fifty individuals from the SPARTAC trial control arm
were selected based on availability of biobanked plasma
samples (Fig. 1a). Individuals came from study sites in the
UK (n¼ 18), South Africa (n¼ 21), Brazil (n¼ 2),
Australia (n¼ 4) and Italy (n¼ 5) and 56% of this cohort
were male. Neutralization breadth and potency of plasma
at the time point prior to initiation of ARTor termination
of the trial (median 157.5 weeks post enrolment) were
determined using a cross-clade 6-virus indicator panel
(JR-CSF, 92BR020, 92RW020, 94UG103, IAVI-C22,
92TH021) previously shown to be predictive of breadth
and potency on a much larger virus panel [4,18].
Neutralization of virions pseudotyped with vesicular
stomatitis virus glycoprotein (VSV-G) was used to
determine nonspecific neutralization. The plasma dilu-
tion required to reduce the level of infection below 50%
(ID50) was calculated and used to assign each patient a
neutralization score representing both breadth and
potency against the indicator panel (Table S1, http://
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Fig. 1. Neutralizing antibody responses in the SPARTAC cohort. (a) SPARTAC cohort demographics. (b) Plasma from the control
arm of the SPARTAC trial were collected and the neutralization breadth and potency measured on a cross-clade HIV-1 indicator
panel. Neutralization scores were calculated as described in the methods section. Percentage of donors with neutralization scores
at defined cut-offs are shown in the pie-graph. Correlation between clinical parameters and neutralization score for (c) weeks post
trial enrolment, (d) years to initiation of ART, (e) age of participant at enrolment, (f) viral load at trial enrolment, (g) viral load at the
time at which neutralization score was measured, (h) CD4þ T-cell count at the time at which neutralization score was measured, (i)
CD4þ T-cell count at less than 6 months post infection. (j) Correlation between CD4 count at the time at which neutralization score
was measured and viral load. Correlations were assessed by Spearman analyses using GraphPad Prism 8: P values and r values are
indicated. Linear, or semi-Log regressions are shown as black lines. ART, antiretroviral therapy; SPARTAC, Short Pulse Anti-
Retroviral Therapy at Seroconversion cohort.
Neutralizing antibodies in SPARTAC cohort Granger et al. 2077
(a) (b) (c) (d)
(e) (f) (g) (h)
Fig. 2. Factors relating to neutralization score. Differences in neutralization score across the whole SPARTAC cohort for: (a)
gender, (b) transmission route [MSM and men to women heterosexual transmission (HSW)], (c) subtype, and (d) country samples
were collected. For (d) an ANOVA analysis showed no significant difference in neutralization score between the countries.
However, a Mann–Whitney U test showed a significantly higher neutralization score in UK vs. South African participants
(P¼0.0247). Difference in neutralization scores for UK and South African participants only for: (e) gender and transmission route
(MSM from UK and HSW women from South Africa) (P¼0.0370), (f) subtype (P¼0.0266), (g) weeks post trial enrolment, and (h)
viral load at bnAb measurement. Statistically significant differences between groups were determined using Mann–Whitney U test
and the respective P values are shown. The horizontal bars represent the median values for each group. ANOVA, analysis of
variance; SPARTAC, Short Pulse Anti-Retroviral Therapy at Seroconversion cohort.links.lww.com/QAD/C206) [36]. One donor (2%) had a
neutralization score greater than 2.5 and five donors
(10%) had a neutralization score greater than 2.0 (Fig. 1b).
Nine donor plasma samples (18%) showed no neutralizing
activity on the viruses tested. This frequency of bnAb
activity is similar to that previously reported for other
HIV-1 infection cohorts [3,24,36–39].
Clinical factors associated with development of
broadly neutralizing antibodies in the Short Pulse
Anti-Retroviral Therapy at Seroconversion cohort
Next, we conducted statistical analyses to identify
potential associations between bnAb development and
clinical factors recorded during the trial (Fig. 1c–h).Similar to previous observations [36,37], the duration of
HIV-1 infection strongly correlated with neutralization
score (Fig. 1c, Spearman r¼ 0.3325, P¼ 0.0183). There
was also a positive correlation between time to initiation
of ART (a reflection on duration of infection) and
neutralization score (Fig. 1d, Spearman r¼ 0.3147,
P¼ 0.0247). There was no correlation with the age (all
of whom were >18 years) and neutralization score
(Fig. 1e). Neutralization score correlated with higher
viral loads at both trial enrolment (Fig. 1f, Spearman
r¼ 0.3870, P¼ 0.0055) and time of bnAb measurement
(Fig. 1g, Spearman r¼ 0.3655, P¼ 0.009). Unlike
previous studies, which found lower CD4þ T-cell count
were associated with bnAb development [3,36,40,41],
2078 AIDS 2021, Vol 35 No 13
Table 1. Specificity of bnAbs present in SPARTAC donors with neutralization score greater than 0.9.
























SUM036008 2.55 – n.d. þ n.d. – þþþ – – N160
SUT036022 2.43 – n.d. þþ n.d. – – þ – N332
SUV054003 2.34 – n.d. þþ n.d. – – – – Unknown
SUP033003 2.17 þ – – – þ – – – Mixed
SUV214008 2.04 – n.d. – n.d. – – þþþ – N332
SAR032004 2.01 þþ – – n.d. – – – – CD4 (dRSC3)
SJU027003 1.87 þ/ – – þ – – þþþ – Mixed
SUM036079 1.65 – – – – – þ – þ Mixed
SUF214003 1.49 – n.d. – n.d. – þ – – N160
SJA023027 1.41 þ/ – – – – – – – CD4 (dRSC3)
SUW036083 1.25 þ/ – – – þ – – – Mixed
SJE023008 1.02 – n.d. – n.d. þ – þ þ Mixed
SUT033001 0.91 – n.d. – n.d.  – – þ Interface
To determine the Env region targeted by the bnAbs present in patient plasma serum, mapping analysis was performed. The symbols represent the
strength of the bnAb phenotype observed. RSC3 (CD4 bs): If the ratio between the area under the curve (AUC) for RSC3/RSC3D371I P363N is 2–3
(þ/), 3–8 (þ) and greater than 8 (þþ). RSC3 competition (CD4 bs): þ if the neutralization is decreased by at least three-fold for RSC3 but not
RSC3D371I/P363N. Only those plasma with binding to RSC3 were tested in the RSC3 competition neutralization. RSC3 (equal binding): if the ratio
between AUC of RSC3/RSC3D371I/P363N) is 1.5 or less and the binding level is as a percentage of the 2G12 endpoint titre as follows;þþ at least
50%,þ is less than 50%, but at least 25%,þ/ is 25% or less. RSC3 competition (equal competition):þ if the neutralization is decreased by3 fold
for both RCS3 and RSC3D371I/P363N. MPER: þ indicates a decrease in plasma neutralization potency of at least three-fold when competed with
soluble MPER peptide. N332A, N160A/K and interface epitopes:þ indicates neutralization of one virus decreased three-to-five fold,þþ indicates
at least two viruses decreased three-to-five fold, þþþ indicates at least five-fold decrease for at least two viruses with glycan site deletion. n.d.
means not determined. SPARTAC, Short Pulse Anti-Retroviral Therapy at Seroconversion cohort. The data relating to this table can be found in
Tables S3 and S6, http://links.lww.com/QAD/C206.there was no correlation between CD4 levels at either
enrolment or at the timepoint at which neutralization was
measured, and neutralization score within the SPARTAC
cohort (Fig. 1h and i). High viral loads did correlate with
low CD4 counts at the time of bnAb screening (Fig. 1j).
Neutralization score was not associated with HIV-1
subtype, route of transmission or gender (Fig. 2a and b).
There were higher neutralization scores in clade B
compared with clade C infected donors but this did not
reach statistical significance (Fig. 2c). However, there was
a significantly higher neutralization score in UK donors
compared with those from South Africa (Fig. 2d), with all
South African donors being female individuals. The small
group sizes for Italy, Brazil and Australia did not allow
meaningful analysis. To understand factors that might
contribute to the higher neutralization scores in UK
donors, we carried out further analysis comparing donors
from South Africa and the UK only (Fig. 2e–i). South
African participants were mostly women infected with
clade C viruses through heterosexual transmission (HSW)
whilst UK participants were mostly MSM infected with
clade B viruses. Statistically significant higher neutraliza-
tion scores were observed in male UK MSM donors
compared with female South African HSW donors
(Fig. 2e) and in UK Clade B infection compared with
South African Clade C infection (Fig. 2f). However, these
differences were not because of duration of HIV infection
(Fig. 2g) or increased viral load (Fig. 2h) in the UK
donors. Whilst multiple factors were correlated withneutralization score whenever analysed individually, in a
multivariate analysis of significant linear correlated
predictors, only viral load at bnAb measurement and
weeks post recruitment were shown to predict the
neutralization score independently (Table S2, http://
links.lww.com/QAD/C206). After the model was
adjusted to contain only weeks post recruitment and
viral load at neutralization score, both were still
independent predictors.
Specificity of broadly neutralizing antibody
responses in the SPARTAC cohort
Next, we mapped the specificity of the bnAb responses in
individuals with neutralization scores above 0.9 (Table 1
and Tables S3–S6, http://links.lww.com/QAD/C206).
Firstly, N332/V3, V2-apex and interface specificity were
determined using neutralization assays on pseudoviruses
where either the N332, N160 and N611/N637 glycan
sites, respectively, had been deleted using an asparagine
to alanine or lysine mutation. Four donors (31%) showed
a reduction in neutralization sensitivity across multiple
viruses for the N332A mutation (3–300-fold), three
donors (23%) showed reduction for the N160A/K
mutations (8–81-fold), and three donors (23%) showed
bnAb specificity against the quaternary epitope at the
gp41/gp120 interface (5–400-fold) (Table S3, http://
links.lww.com/QAD/C206). In some cases, an
enhancement in neutralization potency was observed
when a glycan site was removed, in particular, the N160
glycan (Table S3, http://links.lww.com/QAD/C206).




Fig. 3. Longitudinal analysis of broadly neutralizing antibody development for SPARTAC donors with the highest neutralization
scores. Neutralization by plasma over multiple time-points was measured for each donor on the cross-clade HIV-1 indicator panel.
(a) The geometric mean across the six-virus panel was calculated at each time point for each donor as described in the methods. (b)
Number of viruses neutralized with an ID50 greater than 50 at each time point is shown for each donor. ID50 values for
neutralization of individual viruses at each time point (left axis) as well as geometric mean ID50 across the indicator panel (black
line) and viral load (right-axis, red dotted line) for (c) SUM036008, (d) SUT036022, (e) SUV054003, (f) SUP033003, (g)
SUV214008, (h) SAR032004 and (i) SJU027003.As neutralizing activity was not decreased with glycan
mutations for all the viruses tested, nAbs with narrower
breadth may also be present that contribute to the
plasma neutralization.
MPER specificity was determined using a competition
for neutralization assay with a synthetic MPER peptide.
Plasma was preincubated with MPER peptide before
addition of virus. A decrease in neutralization compared
with no MPER peptide was seen for three donors (23%)
(Table S4, http://links.lww.com/QAD/C206). CD4
specificity was assessed using the resurfaced stabilized
gp120 Core 3 (RSC3), a protein that is selective for
VRC01-like CD4-binding site bnAbs, and a CD4-
binding site knock out mutant (DRSC3, RSC3D371I
P363N) that has decreased binding for VRC01-like
bnAbs [32,33]. Of the 13 donors studied, 5 donors (38%)
showed differential binding between the RSC3 wild-type
and RSC3D371I P363N mutant to some extent (Table 1
and S5, http://links.lww.com/QAD/C206) (although 2
donors had very low endpoint titres). However, similar to
previous studies [32,36], neutralization was not competed
by soluble RSC3 (Table S6, http://links.lww.com/
QAD/C206) suggesting that although RSC3 reactive
Abs can be found in 40–60% of HIV-1-infectedindividuals, the RSC3 reactive Abs are not mediating
the broad neutralization activity. Nevertheless, three of
these donors showed neutralization directed against
another bnAb epitope. Three donors (23%) showed
equally strong reactivity to both RSC3 and DRSC3. As
this probe was engineered to display only the CD4-
binding-site epitope, and as PGT128 and 2G12 bound to
both probes indiscriminately (data not shown) [32], we
reasoned that this phenotype could either be representa-
tive of a V3-glycan epitope or 2G12-like or a CD4-
binding site bnAb, such as N6, which shows no
differential binding to RSC3 and DRSC3 [11].
Overall, seven donors (55%) had bnAb responses
predominantly targeting a single neutralizing epitope, five
donors (38%) had nAbs targeting multiple known bnAb
epitopes and one donor (8%) had undefined specificity.
bnAbs induced against the N332/V3 epitope were most
prevalent in this cohort at the timepoints analysed.
Kinetics of broadly neutralizing antibody
development in the Short Pulse Anti-Retroviral
Therapy at Seroconversion cohort
Using longitudinal plasma samples, we measured the
kinetics of bnAb development for the seven donors with
2080 AIDS 2021, Vol 35 No 13
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Fig. 4. Longitudinal epitope mapping. (a and b) Neutralization of IAVI C22 wild-type (black line) and N332 glycan-site deleted
variant virus (N332A) (red line) compared with the geometric mean ID50 titre (grey line) for SUT036022 and SJU027003,
respectively. (c) Neutralization of JR-CSF wild-type (black line) and N160 glycan-site deleted viruses (N160K) (red line) compared
geometric mean ID50 titre (grey line) for SUM036008. (d and f) Fold-change in area under the curve (AUC) for RSC3 CD4-binding
site mutant compared with RSC3 WT over the course of infection (red line, right-axis) and geometric mean ID50 titre on virus
indicator panel (black line, left-axis) for SUP033003, SAR032004 and SUT036022, respectively.the highest neutralization scores (Fig. 3). In all donors,
there was a delay in development of heterologous
neutralization following HIV-1 infection, and the pattern
and timing of bnAb development differed between
donors (Fig. 3a and b). For example, heterologous
neutralization in donor SUV214008 arose late in
infection, after 180 weeks but the bnAbs that arose
neutralized all viruses in the panel to some extent
(Fig. 3g). In contrast, heterologous neutralization activity
started to appear after 50 weeks in donor SJU027003 but
the neutralization breadth took time to develop,
increasing incrementally to reach neutralization of five
viruses after 160 weeks (Fig. 3i). The geometric mean
titres peak in some donors (e.g. SJU027003) with little or
no increase in titres thereafter. Development of bnAbs
had no effect on viral load in any of the donors (Fig. 3c–i).
We further determined the bnAb specificity over time in
some donors using longitudinal plasma samples (Fig. 4).
For donors with an N332/V3 phenotype (SUT036022
and SJU027003) or N160 phenotype (SUM036008),
nAbs sensitive to the N332A mutation or N160K
mutation arose at the same timepoint as heterologous
neutralization (Fig. 4a–c). However, donors with a CD4-binding site phenotype (SUP033003 and SAR032004)
had CD4-binding site-specific Abs present before
heterologous neutralization arose (Fig. 4d and e,
respectively). This observation, combined with the lack
of RSC3 competition for neutralization, further suggests
this epitope is not responsible for the broadly neutralizing
activity in plasma from these donors. Interestingly, donor
SUT036022, which had strong binding to both the
RSC3 wild-type and mutant glycoproteins at late
infection timepoints, showed a CD4-binding-site phe-
notype preceding the development of heterologous
neutralization with N332/V3 bnAb specificity, which
disappeared later in infection (Fig. 4f).Discussion
Here, we investigated the bnAb responses in 50 ART-
naive individuals from the control arm of the SPARTAC
trial [31], a primary HIV-1 infection cohort. Similar to
other HIV-1 cohort studies [36,40,42,43], plasma
neutralization correlated with both duration of HIV-1
infection and viral load, suggesting that both extended
Neutralizing antibodies in SPARTAC cohort Granger et al. 2081levels of antigenic stimulation through chronic infection
and high levels of viral antigen are required for the
extensive somatic hypermutation that is a characteristic of
many HIV-1 bnAbs. Alternatively, these factors increase
the probability of activating the germline BCRs that can
subsequently develop into bnAbs. When bnAb develop-
ment was analysed longitudinally (Fig. 3), heterologous
neutralization first arose between 50 and 180 weeks
postinfection and neutralization breadth (i.e. neutralizing
five of six viruses in the indicator panel) arose between
132 and 204 weeks post infection or 24–180 weeks
following heterologous neutralization similar to other
studies of bnAb development in adults [3,36,39]. These
data confirm that early bnAb development is not
common (although this has been observed in some
infants [44,45]), and is not associated with clinical
outcome. In contrast to other studies [3,36,40,41], CD4
levels at both recruitment (<6 months post infection) and
the time of bnAb measurement did not negatively
correlate with neutralization score. There was, however, a
strong negative correlation between viral load and CD4
levels (Fig. 1j), which may suggest that reduced CD4
count is a consequence of high viral replication rather
than contributing to bnAb development. Not all
individuals with high viral load or long duration of
HIV-1 infection developed a bnAb response indicating
that other factors are important for bnAb induction.
Due to the relatively small size and the nature of the
individuals making up the SPARTAC cohort, it is
difficult to tease apart the impact of individual factors,
such as HIV-1 subtype, gender, transmission route and
location on neutralization score. However, statistically
higher neutralization scores were observed in UK donors
compared with South African donors. Although not
statistically significant, we observed proportionally more
male than female participants with neutralization scores
above 2.0. In previous analyses of bnAb responses in
injecting drug users (IDU) from both the Amsterdam and
Swiss cohorts, a significantly lower prevalence of bnAb
responses was observed in female compared with male
participants [46]. Further, across the whole Swiss cohort,
female donors showed slightly lower neutralization
breadth than male donors [40]. However, as the route
of transmission for male and female participants
predominantly differed for members of the SPARTAC
cohort, it cannot be concluded that gender alone is
responsible for this difference. Black ethnicity has recently
been reported to be a strong correlate for bnAb induction
in the Swiss cohort [40,42]; however, this information
was not available for all SPARTAC participants.
Within the SPARTAC cohort, there is a trend towards
higher neutralization scores following a subtype B HIV-1
infection compared with subtype C infection. Conflict-
ing associations between bnAb induction and HIV-1
subtype have been previously reported within other
cohorts of HIV-1-infected individuals [36,40]. Forexample, no difference in bnAb induction was observed
between subtype B and nonsubtype B donors in the Swiss
cohort [40] yet a strong correlation between HIV-1
subtype C infection and neutralization score was observed
in the IAVI Protocol C cohort [36] (although the
significance was reduced when considered in a multivar-
iate analysis).
Similar to previous cohort studies, the bnAb activity in
SPARTAC donors predominantly mapped to one or two
bnAb epitopes. We note that subtle changes in neutraliza-
tion sensitivity for mutations at several bnAb epitopes were
observed in some plasma (Tables S3–S8, http://links.lww.-
com/QAD/C206). The nAbs may also contribute to the
overall plasma neutralization breadth and potency. bnAbs
targeting glycan-dependent epitopes (V3/N332, N160/
V2, and interface epitopes) were particularly prevalent in
the SPARTAC cohort [8 of the top 13 donors (62%)]. The
number of donors in the SPARTAC cohort that developed
bnAbs was too small to find any meaningful differences
between HIV-1 subtype and bnAb epitope. When
comparing the kinetics of bnAb development with the
specificity of the bnAb response, we see that for the donors
that target the V3/N332 and N160/V2 epitopes,
induction of heterologous neutralization coincides with
bnAbs targeting the glycan epitopes. The bnAb responses
then broaden incrementally over time as the infection
proceeds. This trend in bnAb development was previously
seen in donors PC76 from IAVI protocol C [17] and
CAP177 and CAP314 from the CAPRISA cohort [47]
who developed N332/V3 bnAbs, and donor PC64 from
the IAVI protocol C cohort who developed N160/V2
bnAbs [48]. The role that more strain-specific nAbs play in
development of bnAb lineages should be investigated in
future co-evolution studies.
Although CD4-binding site Abs were common in the
SPARTAC cohort (38% of donors showed differential
binding to the RSC3 and RSC3 mutant probe to some
extent in ELISA), the development of CD4-binding site
bnAbs was rare. In the IAVI Protocol C cohort, CD4-
binding site Abs took longer to develop than the N332/
V3 and N160/V2 bnAbs, presumably because of the very
high level of somatic hypermutation required for
neutralization breadth [36]. Indeed, Abs with differential
binding to the RSC3 protein and CD4-binding site
knockout were observed prior to heterologous neutrali-
zation suggesting higher mutation levels/antigen stimu-
lation are required for CD4-binding site-targeted nAbs to
acquire neutralization breadth (Fig. 4).
In conclusion, we show that in the SPARTAC cohort,
development of plasma neutralization breadth and
potency correlates with duration of HIV infection and
high viral loads. We identify individuals for which more
in-depth studies on antibody–viral co-evolution will be
conducted to better understand how bnAbs arise during
natural infection at the molecular level.
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